Daiichi Sankyo and Merck announced a significant regulatory milestone with the FDA’s acceptance and Priority Review of ifinatamab deruxtecan (I-DXd), a potentially first-in-class therapeutic targeting an innovative cancer pathway. According to BusinessWire.com, the antibody drug conjugate is being evaluated for adult patients with extensive-stage small cell lung cancer (ES-SCLC) who experienced disease progression after platinum-based chemotherapy, a patient population with severely limited treatment options.
Addressing an Urgent Medical Need
Small cell lung cancer remains one of oncology’s most challenging malignancies. Approximately 250,000 new SCLC cases occur annually worldwide, with roughly 27,000 diagnosed in the United States alone, representing approximately 12% of all lung cancer cases. The disease is notably aggressive, progressing rapidly to metastatic stages with a distressing five-year survival rate. Despite available standard-of-care treatments, patients whose disease advances after initial platinum-based chemotherapy face dwindling therapeutic options.
“Small cell lung cancer remains one of the toughest cancers to treat, with few options if the disease progresses after standard of care treatments,” said Eliav Barr, MD, Senior Vice President and Chief Medical Officer at Merck Research Laboratories. The FDA’s Priority Review designation underscores recognition of this unmet medical need and the potential impact of this novel approach.
Novel Therapeutic Target
Ifinatamab deruxtecan represents a fundamentally new treatment strategy through its targeting of B7-H3, a transmembrane protein belonging to the B7 family of immune-regulating molecules. B7-H3 is significantly overexpressed across a wide range of cancers, including SCLC, with overexpression correlating directly to poor prognosis. Importantly, no B7-H3 directed medicines are currently approved for cancer treatment, making this pathway entirely unexploited therapeutically.
The therapeutic is engineered as a B7-H3 directed ADC utilizing Daiichi Sankyo’s proprietary DXd technology platform. This design consists of a humanized antibody attached to multiple topoisomerase I inhibitor payloads through specialized cleavable linkers, enabling targeted drug delivery directly to cancer cells expressing B7-H3.
Compelling Clinical Evidence
The FDA’s Priority Review decision is based on results from the IDeate-Lung01 Phase 2 trial, supported by data from the IDeate-PanTumor01 Phase 1/2 trial. The IDeate-Lung01 study enrolled 187 patients across Asia, Europe, and North America with ES-SCLC who had received at least one prior line of platinum-based chemotherapy. The primary endpoint evaluated objective response rate as assessed by blinded independent central review, with secondary endpoints including progression-free survival, duration of response, and overall survival.
Accelerated Regulatory Pathway
Ifinatamab deruxtecan previously received Breakthrough Therapy Designation from the FDA in August 2025, recognizing its potential to provide substantial improvements over existing therapeutic approaches. The current Priority Review status expedites the regulatory process, with the FDA’s PDUFA action date set for October 10, 2026.
Additionally, the FDA is evaluating the application under two specialized programs: Real-Time Oncology Review (RTOR), which allows component review before complete submission, and Project Orbis, enabling concurrent international regulatory submissions.
Comprehensive Development Program
The collaborative partnership between Daiichi Sankyo and Merck reflects confidence in this platform, with three Phase 3 trials currently underway evaluating ifinatamab deruxtecan across SCLC, castration-resistant prostate cancer, and esophageal squamous cell carcinoma, demonstrating the broad potential of B7-H3 targeting in oncology.
